Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2012
Press Release
2012 Press Release
RSS
Press Release
12.17.2012
Changes in Significant Shareholders
11.27.2012
Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)
11.27.2012
Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration
11.01.2012
Notice of Cancellation of Treasury Shares
10.03.2012
Santen to Renew the Sante 40 OTC Eye Drop Series
09.28.2012
Intravitreal VEGF Inhibitor "EYLEA Solution for Intravitreal Injection" and "EYLEA Intravitreal Injection KIT" Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
09.25.2012
Notice on the Establishment of a New Sales and Marketing Company in China
09.25.2012
Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs
08.30.2012
Notification Regarding Result and Completion of Acquisition of Treasury Stock and Tender Offer of Treasury Stock
08.01.2012
Notice of Acquisition and Tender Offer of Treasury Stock
07.04.2012
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
06.25.2012
FDA Approves enVista, a Single-Piece Intraocular Lens, Made from the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS
06.20.2012
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
05.08.2012
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
05.08.2012
Announcement of the conclusion of the agreement on co-promotion of VEGF Trap-Eye (aflibercept intravitreal injection)
05.08.2012
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
05.08.2012
Notice of the Nominations for the members of the Board of Directors
03.09.2012
Notice of the appointment of Corporate Officers
03.01.2012
Santen to Launch Sante Medical Guard OTC Eye Drop
02.14.2012
FDA Approves ZIOPTAN (tafluprost ophthalmic solution),Merck's Once-Daily, Preservative-Free Ophthalmic Medication
02.07.2012
Notice on the Establishment of Holding Company in Europe
01.24.2012
Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA
News Archive
